Medpage Today on MSN2mon
FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines
The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial ...
Hosted on MSN11mon
Pfizer is looking to expand it’s RSV Vaccine Abrysvo to more people
Right now, Pfizer is in phase 3 of a clinical trial of people 18 to 59. Pfizer’s RSV vaccine is Abrysvo. Pfizer will investigate the safety of the vaccine in adults at risk for the illness.
pharmaphorum5mon
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the ...